---
title: MI Mortality Risk and Between-hospital Risk Variation in the United Kingdom and Sweden
nct_id: NCT01359033
overall_status: COMPLETED
sponsor: University College, London
study_type: OBSERVATIONAL
primary_condition: Acute Myocardial Infarction
countries: Sweden, United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01359033.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01359033"
ct_last_update_post_date: 2017-11-17
last_seen_at: "2026-05-12T06:42:14.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# MI Mortality Risk and Between-hospital Risk Variation in the United Kingdom and Sweden

**Official Title:** Compare the Patient Risk and Between-hospital Variation in Myocardial Infarction Mortality in the United Kingdom and Sweden

**NCT ID:** [NCT01359033](https://clinicaltrials.gov/study/NCT01359033)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 510863
- **Lead Sponsor:** University College, London
- **Collaborators:** NICOR/MINAP, the United Kingdom, National Institute for Cardiovascular Outcomes Research, MINAP: Myocardial Ischaemia National Audit Project, SWEDEHEART/RIKS-HIA, Sweden, SWEDEHEART: Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies, RIKS-HIA: Register of Information and Knowledge about Swedish Heart Intensive care Admissions
- **Conditions:** Acute Myocardial Infarction
- **Start Date:** 2011-03
- **Completion Date:** 2014-12
- **CT.gov Last Update:** 2017-11-17

## Brief Summary

The study aims to investigate the differences in survival trajectories and hospital variability in myocardial infarction (MI) mortality rates in the UK and Sweden.

## Detailed Description

Limited evidence is available in comparing hospital level care and reference mortality risks between countries, due to the scarce availability of nationwide coronary heart disease data. The demographics and medical expenditure percentage are comparable in the United Kingdom and Sweden; however, the in-hospital case-fatality rates within 30 days after admission for acute myocardial infarction was greater in the UK than Sweden (6.3% versus 2.9%)(OECD, 2009). To investigate the discrepancy, the current study aims to compare the mortality risk differences and associated explanatory factors between the two countries. Results of the study can contribute to myocardial infarction care implementation in the UK and Sweden.

The UK Myocardial Ischaemia National Audit Project (MINAP)and Register of Information and Knowledge about Swedish Heart Intensive care Admissions (RIKS-HIA) are few quality national registries currently available for acute coronary syndrome. Using data from the MINAP and RIKS-HIA, we propose to investigate (1)the survival trajectories for a reference patient with myocardial infarction and (2) hospital variability in myocardial infarction mortality rate in the UK and Sweden, adjusted for important patient-level and hospital-level covariates.

## Eligibility

- **Minimum age:** 30 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients aged above 30 years old who had hospital admission for acute myocardial infarction.
* Admission period ranged from 1st January, 2004 to 31th December, 2008.

Exclusion Criteria:

* Patients with missing data in the admission time and/or primary outcomes.
```

## Arms

- **MINAP cohort** — The Myocardial Ischaemia National Audit Project (MINAP) was established in 1999, in response to the national service framework (NSF) for coronary heart disease, to examine the quality of management of heart attacks (myocardial infarction) in hospitals in England and Wales.
- **RIKS-HIA cohort** — The Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) has been established to record clinical and treatment information for all patients admitted to the coronary care units in Sweden from 1995.

## Primary Outcomes

- **30-day mortality** _(time frame: 30-day)_ — all-cause mortality at 30-day following hospitalization for acute Myocardial Infarction

## Secondary Outcomes

- **1-year mortality** _(time frame: 1 year)_

## Locations (2)

- Uppsala Clinial Research Center, Uppsala, Sweden
- University College London, London, United Kingdom

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.uppsala clinial research center|uppsala||sweden` — added _(2026-05-12)_
- `locations.university college london|london||united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01359033.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01359033*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*